BioCentury | Apr 6, 2018
Financial News

Intercept raises $250M in two offerings

...the sale of 1.6 million shares at the same price in a private placement to Genextra S.p.A....
BioCentury | Apr 5, 2018
Financial News

Intercept raises $250M in two offerings

...the sale of 1.6 million shares at the same price in a private placement to Genextra S.p.A....
BioCentury | Jan 13, 2014
Finance

Interception and goal

...shares at $33.01 for a postmoney valuation of $622.6 million. Intercept's major early investors were Genextra S.p.A....
...are worth $770 million, representing a 30x multiple, not counting shares it has already sold. Genextra...
...are worth $2.6 billion, representing a 32x multiple, not counting shares it has already sold. Genextra...
BioCentury | Oct 14, 2013
Financial News

Intercept Pharmaceuticals financial update

...Intercept shareholders OrbiMed Advisors and Genextra S.p.A. (Milan, Italy) plan to sell 1.5 million shares of Intercept...
...The shareholders expect to receive $93.8 million through the sale. BofA Merrill Lynch is underwriter. Genextra's...
BioCentury | Sep 2, 2013
Clinical News

GNX-5086: Phase I started

...Dutch Phase I trial to evaluate single ascending-doses IV GNX-5086 in about 33 healthy volunteers. Genextra S.p.A....
BioCentury | Aug 5, 2013
Financial News

EryDel completes venture financing

...Drug delivery, Neurology Date completed: 7/31/13 Type: Venture financing Raised: €15 million ($19.9 million) Investors: Genextra...
BioCentury | Aug 5, 2013
Company News

EryDel board of directors update

...EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Appointed: Lorenzo Tallargio, CEO of Genextra S.p.A. WIR Staff...
BioCentury | Aug 1, 2013
Financial News

EryDel raises EUR 15 million in B round

...led by new investor Genextra S.p.A. , with participation from existing investors Innogest and Focus Gestioni. Genextra's...
BioCentury | Aug 13, 2012
Financial News

Intercept Pharmaceuticals completes venture financing

...Business: Hepatic, Endocrine/Metabolic Date completed: 8/9/12 Type: Venture financing Raised: $30 million Investors: OrbiMed Advisors; Genextra WIR...
BioCentury | Aug 10, 2012
Financial News

Intercept raises $30M in series C

...N.Y.) raised $30 million in a series C round led by OrbiMed Advisors. Existing investor Genextra S.p.A....
Items per page:
1 - 10 of 18
BioCentury | Apr 6, 2018
Financial News

Intercept raises $250M in two offerings

...the sale of 1.6 million shares at the same price in a private placement to Genextra S.p.A....
BioCentury | Apr 5, 2018
Financial News

Intercept raises $250M in two offerings

...the sale of 1.6 million shares at the same price in a private placement to Genextra S.p.A....
BioCentury | Jan 13, 2014
Finance

Interception and goal

...shares at $33.01 for a postmoney valuation of $622.6 million. Intercept's major early investors were Genextra S.p.A....
...are worth $770 million, representing a 30x multiple, not counting shares it has already sold. Genextra...
...are worth $2.6 billion, representing a 32x multiple, not counting shares it has already sold. Genextra...
BioCentury | Oct 14, 2013
Financial News

Intercept Pharmaceuticals financial update

...Intercept shareholders OrbiMed Advisors and Genextra S.p.A. (Milan, Italy) plan to sell 1.5 million shares of Intercept...
...The shareholders expect to receive $93.8 million through the sale. BofA Merrill Lynch is underwriter. Genextra's...
BioCentury | Sep 2, 2013
Clinical News

GNX-5086: Phase I started

...Dutch Phase I trial to evaluate single ascending-doses IV GNX-5086 in about 33 healthy volunteers. Genextra S.p.A....
BioCentury | Aug 5, 2013
Financial News

EryDel completes venture financing

...Drug delivery, Neurology Date completed: 7/31/13 Type: Venture financing Raised: €15 million ($19.9 million) Investors: Genextra...
BioCentury | Aug 5, 2013
Company News

EryDel board of directors update

...EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Appointed: Lorenzo Tallargio, CEO of Genextra S.p.A. WIR Staff...
BioCentury | Aug 1, 2013
Financial News

EryDel raises EUR 15 million in B round

...led by new investor Genextra S.p.A. , with participation from existing investors Innogest and Focus Gestioni. Genextra's...
BioCentury | Aug 13, 2012
Financial News

Intercept Pharmaceuticals completes venture financing

...Business: Hepatic, Endocrine/Metabolic Date completed: 8/9/12 Type: Venture financing Raised: $30 million Investors: OrbiMed Advisors; Genextra WIR...
BioCentury | Aug 10, 2012
Financial News

Intercept raises $30M in series C

...N.Y.) raised $30 million in a series C round led by OrbiMed Advisors. Existing investor Genextra S.p.A....
Items per page:
1 - 10 of 18